Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM.

J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628. Epub 2009 Jan 26.

2.

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D.

J Clin Oncol. 1998 Jan;16(1):229-36.

PMID:
9440747
3.

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM.

J Clin Oncol. 2006 Jan 20;24(3):500-6.

PMID:
16421427
4.

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.

J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Epub 2012 Jun 14. Erratum in: J Nucl Med. 2016 Jun;57(6):988.

5.

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.

Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA, Matthay KK.

Pediatr Blood Cancer. 2005 Mar;44(3):232-9.

PMID:
15490487
6.

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.

DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK.

J Clin Oncol. 2004 Jun 15;22(12):2452-60.

PMID:
15197208
7.

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK.

Biol Blood Marrow Transplant. 2015 Apr;21(4):673-81. doi: 10.1016/j.bbmt.2014.12.008. Epub 2015 Jan 30.

8.

131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.

French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K.

Pediatr Blood Cancer. 2013 May;60(5):879-84. doi: 10.1002/pbc.24351. Epub 2012 Sep 28.

PMID:
23024113
9.

Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, Mosse YP.

Pediatr Blood Cancer. 2011 Dec 15;57(7):1124-9. doi: 10.1002/pbc.23062. Epub 2011 Apr 14.

PMID:
21495159
10.

Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.

Goldberg SS, DeSantes K, Huberty JP, Price D, Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK.

Med Pediatr Oncol. 1998 Jun;30(6):339-46.

PMID:
9589082
11.

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK.

Clin Cancer Res. 2012 May 1;18(9):2679-86. doi: 10.1158/1078-0432.CCR-11-3201. Epub 2012 Mar 15.

12.

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B.

J Nucl Med. 2001 Nov;42(11):1713-21.

13.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.

PMID:
17369569
14.

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.

Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JL, Hutchinson RJ.

J Clin Oncol. 2002 Apr 15;20(8):2142-9.

PMID:
11956276
15.

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP.

J Clin Oncol. 2006 Jul 20;24(21):3423-30. Erratum in: J Clin Oncol. 2006 Sep 1;24(25):4223. Reynolds, Patrick C [corrected to Reynolds, C Patrick].

PMID:
16849757
16.

High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.

Toporski J, Garkavij M, Tennvall J, Ora I, Gleisner KS, Dykes JH, Lenhoff S, Juliusson G, Scheding S, Turkiewicz D, Békássy AN.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1077-85. doi: 10.1016/j.bbmt.2009.05.007. Epub 2009 Jul 8.

17.

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.

Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, Troncone L, Mastrangelo R.

Br J Cancer. 2001 Feb;84(4):460-4.

18.

3D conformal radiotherapy and cisplatin for recurrent malignant glioma.

VanderSpek L, Fisher B, Bauman G, Macdonald D.

Can J Neurol Sci. 2008 Mar;35(1):57-64.

PMID:
18380278
19.

A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.

Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.

Bone Marrow Transplant. 2000 Jan;25(1):5-11.

20.

Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.

Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP.

Clin Cancer Res. 2002 Feb;8(2):413-8.

Supplemental Content

Support Center